PRPH ProPhase Labs, Inc.
Mergers ·
Zoar Limited filed a Form F-4 on September 10, 2026 that includes Impact BioMedical's preliminary proxy statement for the proposed business combination with Zoar Labs Limited.
ProPhase Labs signed a senior secured convertible loan with J.J. Astor & Co. on July 31, 2026. The note has an original principal of $2,085,000, a funding amount of $1,440,000 and a final maturity of July 31, 2027.
ProPhase Labs, Inc. describes itself as a diversified biotech, genomics and consumer products company. It develops and commercializes novel drugs, dietary supplements and compounds, and offers human genomic testing. Its subsidiary DNA Complete, with sequencing performed at Nebula Genomics, sells whole genome sequencing products direct to consumers online, with plans to sell in food, drug and mass retail stores and to provide testing for universities conducting genomic research. DNA Complete offers ancestry and personalized health reports. The company's BE-Smart test is an esophageal pre-cancer diagnostic screening test that is still under development, aimed at early detection of progression from Barrett's esophagus to esophageal adenocarcinoma. The company plans to commercialize it as a Laboratory Developed Test. The company also markets dietary supplements under the TK Supplements brand. Its COVID-19 testing subsidiary, ProPhase Diagnostics, has not provided diagnostic testing services since the fourth quarter of 2024, and its entities filed voluntary Chapter 11 petitions in September 2025 in the United States Bankruptcy Court for the District of New Jersey.
| Product or program | What it is | Stage |
|---|---|---|
| BE-Smart Esophageal Pre-Cancer test | Screening test for progression from Barrett's esophagus to esophageal adenocarcinoma | Under development |
| DNA Complete whole genome sequencing | Direct-to-consumer genomic tests with Essential, Pro and Elite tiers | Offered direct to consumers online |
| DNA Expand | Platform for uploading prior DNA data to obtain health and wellness reports | Offered |
| TK Supplements | Dietary supplements | Marketed |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $4.3 million | $6.8 million |
| Research and development | $107,000 | $594,000 |
| Net income (loss) | -$14.7 million | -$53.4 million |
| Cash from operations | -$8.3 million | -$17.5 million |
| Cash and equivalents | $90,000 | $678,000 |
| Short-term investments | $0 | $3.1 million |
Our latest story on this, dated Jul 31, 2026: "ProPhase Labs issues $2,085,000 senior secured convertible note". The story links the filing or release it is based on. Read the story.
ProPhase Labs, Inc. trades under the ticker PRPH on OTC.
ProPhase Labs, Inc. is listed on OTC.
Our directory records ProPhase Labs, Inc. under United States.
aibio.space lists ProPhase Labs, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
ProPhase Labs, Inc. describes itself as a diversified biotech, genomics and consumer products company. It develops and commercializes novel drugs, dietary supplements and compounds, and offers human genomic testing.
BE-Smart Esophageal Pre-Cancer test: Screening test for progression from Barrett's esophagus to esophageal adenocarcinoma Stage: Under development.
DNA Complete whole genome sequencing: Direct-to-consumer genomic tests with Essential, Pro and Elite tiers Stage: Offered direct to consumers online.
$4.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
ProPhase Labs, Inc. reported a net loss of $14.7 million for the fiscal year ended Dec 31, 2025, and used $8.3 million of cash in operations, per its annual report to the SEC.
$107,000 in the fiscal year ended Dec 31, 2025, per its annual report.
$20,000 in cash at Jun 30, 2026, per its 10-Q.
Our latest story on ProPhase Labs, dated Jul 31, 2026: "ProPhase Labs issues $2,085,000 senior secured convertible note". ProPhase Labs signed a senior secured convertible loan with J.J. Astor & Co. on July 31, 2026. The note has an original principal of $2,085,000, a funding amount of $1,440,000 and a final maturity of July 31, 2027. Source.
ProPhase Labs is named in 1 of our story about other companies, most recently: "Impact BioMedical reports Zoar F-4 filing in business combination" (Sep 17, 2026). Source.
Press Follow on this page to add ProPhase Labs to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming ProPhase Labs so far, in Debt Financing, Mergers.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio